Brief: Halozyme Sues Merck For Patent Infringement Over Subcutaneous Keytruda Formulation
24/04/2025 13:56
April 24 (Reuters) - Halozyme Therapeutics Inc HALO.O: HALOZYME SUES MERCK FOR PATENT INFRINGEMENT OVER SUBCUTANEOUS KEYTRUDA FORMULATION HALOZYME THERAPEUTICS INC - SEEKS DAMAGES AND INJUNCTIVE RELIEF AGAINST MERCK Source text: ID:nPn6jd0F4a Further company coverage: HALO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Halozyme Therapeutics
See all newsUS RESEARCH ROUNDUP-BlackRock, Evercore, Goldman Sachs
Halozyme wins court order to block Merck's injected Keytruda in select European markets (updated)
US STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
Halozyme wins court order to block Merck's injected Keytruda in select European markets